These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26324819)

  • 1. "Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis." Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58-64.
    Eur Respir Rev; 2015 Sep; 24(137):545. PubMed ID: 26324819
    [No Abstract]   [Full Text] [Related]  

  • 2. "Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis." Yasuhiro Kondoh, Vincent Cottin and Kevin K. Brown.
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29653947
    [No Abstract]   [Full Text] [Related]  

  • 3. "Idiopathic inflammatory myopathies and the lung." Jean-Christophe Lega, Quitterie Reynaud, Alexandre Belot, Nicole Fabien, Isabelle Durieu and Vincent Cottin. Eur Respir Rev 2015; 24: 216-238.
    Eur Respir Rev; 2015 Sep; 24(137):545. PubMed ID: 26324818
    [No Abstract]   [Full Text] [Related]  

  • 4. "Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis." Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher. Eur Respir J 2016; 47: 1776-1784.
    Eur Respir J; 2016 Aug; 48(2):593. PubMed ID: 27478193
    [No Abstract]   [Full Text] [Related]  

  • 5. "Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis." M. Kolb, B. Crestani and T.M. Maher.
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38537950
    [No Abstract]   [Full Text] [Related]  

  • 6. "Lung biopsy in interstitial lung disease: balancing the risk of surgery and diagnostic uncertainty." Vincent Cottin. Eur Respir J 2016; 48: 1274-1277.
    Eur Respir J; 2016 Dec; 48(6):1819. PubMed ID: 27903698
    [No Abstract]   [Full Text] [Related]  

  • 7. "Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease." Laurent Savale, Anoosha Habibi, François Lionnet, Bernard Maitre, Vincent Cottin, Xavier Jais, Ari Chaouat, Elise Artaud-Macari, Matthieu Canuet, Grégoire Prevot, Christelle Chantalat-Auger, David Montani, Olivier Sitbon, Fréderic Galacteros, Gérald Simonneau, Florence Parent, Pablo Bartolucci and Marc Humbert.
    Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 32001502
    [No Abstract]   [Full Text] [Related]  

  • 8. "Characterisation of patients with interstitial pneumonia with autoimmune features." Justin M. Oldham, Ayodeji Adegunsoye, Eleanor Valenzi, Cathryn Lee, Leah Witt, Lena Chen, Aliya N. Husain, Steven Montner, Jonathan H. Chung, Vincent Cottin, Aryeh Fischer, Imre Noth, Rekha Vij and Mary E. Strek.
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28495685
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.
    Cottin V; Maher T
    Eur Respir Rev; 2015 Mar; 24(135):58-64. PubMed ID: 25726556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg).
    Krauss E; Tello S; Wilhelm J; Schmidt J; Stoehr M; Seeger W; Dartsch RC; Crestani B; Guenther A
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33266405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
    Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
    BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis." Bridget F. Collins and Ganesh Raghu.
    Eur Respir Rev; 2019 Dec; 28(154):. PubMed ID: 31722893
    [No Abstract]   [Full Text] [Related]  

  • 13. "The therapy of idiopathic pulmonary fibrosis: what is next?" Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi,
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31554706
    [No Abstract]   [Full Text] [Related]  

  • 14. "Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis." Kevin R. Flaherty, Charlene D. Fell, J. Terrill Huggins, Hilario Nunes, Robert Sussman, Claudia Valenzuela, Ute Petzinger, John L. Stauffer, Frank Gilberg, Monica Bengus and Marlies Wijsenbeek.
    Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30287496
    [No Abstract]   [Full Text] [Related]  

  • 15. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
    Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW
    Respiration; 2017; 94(5):408-415. PubMed ID: 28898890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
    Lancaster LH; de Andrade JA; Zibrak JD; Padilla ML; Albera C; Nathan SD; Wijsenbeek MS; Stauffer JL; Kirchgaessler KU; Costabel U
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29212837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study.
    Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Life Experience with Pirfenidone in Idiopathic Pulmonary Fibrosis in Argentina. A Retrospective Multicenter Study.
    Caro FM; Alberti ML; Campins F; Enghelmayer JI; Fernández ME; Lancellotti D; Papucci T; Sebastiani JA; Paulin F
    Arch Bronconeumol (Engl Ed); 2019 Feb; 55(2):75-80. PubMed ID: 30049557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.